Company Tibet Duo Rui Pharmaceutical Co., Ltd.

301075

CNE100004RW5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 30/10/2026			5-day change	1st Jan Change
45.55 ^CNY	-5.46%		-15.08%	-23.66%

28/10	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
29/09	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2026.	CI

Business description: Tibet Duo Rui Pharmaceutical Co., Ltd.

Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Number of employees: 461

Sales by Activity: Tibet Duo Rui Pharmaceutical Co., Ltd.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
Preparations	-	30Cr	23Cr	19Cr	5.54Cr
Active Pharmaceutical Ingredient (api)	-	-	-	1.03Cr	4.97Cr
Intermediate	-	10Cr	9.96Cr	3.8Cr	3.9Cr
Others	6.43Cr	-	-	55.1L	1.01Cr
Sodium Acetate Ringer's Injection	47Cr	-	-	-	-

See all business segments

Geographical breakdown of sales: Tibet Duo Rui Pharmaceutical Co., Ltd.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
China	53Cr	40Cr	33Cr	24Cr	15Cr

See all geographic segments

Executive Committee: Tibet Duo Rui Pharmaceutical Co., Ltd.

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	01/12/2018
Chao Li DFI	Director of Finance/CFO	47	01/05/2017
Fen Jin DFI	Director of Finance/CFO	46	01/12/2017
Ying Liu IRC	Investor Relations Contact	39	-
Bo Ao PRN	Corporate Officer/Principal	40	23/03/2022

See TIBET DUO RUI PHARMACEUTICAL CO., LTD. governance

Composition of the Board of Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Director	Title	Age	Since
Yong Deng CHM	Chairman	60	01/12/2017
Shao Zhong Zhang BRD	Director/Board Member	70	21/02/2020
Qin Deng BRD	Director/Board Member	58	21/02/2020
Ying Fei Liu BRD	Director/Board Member	48	21/02/2020
Fei Qi BRD	Director/Board Member	49	21/02/2020
Fen Jin BRD	Director/Board Member	46	15/04/2022
Yun Guo Wang BRD	Director/Board Member	54	15/04/2022

Composition of the Board of Directors

Shareholders: Tibet Duo Rui Pharmaceutical Co., Ltd.

Name	Stocks	%	Valuation
Hongde Fund Management Co., Ltd. 0.0616 %	16,900	0.0616 %	159 211 ¥
China Asset Management Co., Ltd. 0.0394 %	10,800	0.0394 %	101 744 ¥
Bank of Beijing Scotiabank Asset Management Co., Ltd. 0.002188 %	600	0.002188 %	5 652 ¥
Cinda Fund Management Co. Ltd. 0.001823 %	500	0.001823 %	4 710 ¥
CCB Principal Asset Management Co., Ltd. 0.001094 %	300	0.001094 %	2 826 ¥

List of TIBET DUO RUI PHARMACEUTICAL CO., LTD. shareholders

Company details: Tibet Duo Rui Pharmaceutical Co., Ltd.

Tibet Duo Rui Pharmaceutical Co., Ltd.

3/F, Building 1, Biomedical Park

854000, Changdu

http://www.duoruiyy.com

address Tibet Duo Rui Pharmaceutical Co., Ltd.(301075)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	-5.46%	-15.08%	-18.91%	+57.78%	55Cr
ELI LILLY AND COMPANY	+3.19%	+11.31%	+64.28%	+155.66%	1,26300Cr
JOHNSON & JOHNSON	-0.73%	+3.56%	+44.65%	+83.74%	66TCr
ABBVIE INC.	+1.41%	+3.24%	+35.25%	+106.98%	52TCr
ROCHE HOLDING AG	+0.42%	+3.20%	+55.81%	+69.71%	39TCr
MERCK & CO., INC.	+2.18%	+2.93%	+73.90%	+45.38%	37TCr
NOVARTIS AG	+1.12%	+4.52%	+34.76%	+57.00%	31TCr
ASTRAZENECA PLC	+6.96%	+8.86%	+11.95%	+35.06%	29TCr
AMGEN INC.	+1.15%	+6.09%	+56.15%	+78.66%	25TCr
GILEAD SCIENCES, INC.	+3.06%	+9.38%	+42.48%	+112.84%	21TCr
Average	+1.33%	+4.14%	+40.03%	+80.28%	42.62TCr
Weighted average by Cap.	+2.01%	+6.60%	+50.50%	+99.18%